6562 Stock Overview
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
UBI Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$14.25 |
| 52 Week High | NT$42.54 |
| 52 Week Low | NT$10.00 |
| Beta | 0.19 |
| 1 Month Change | -49.29% |
| 3 Month Change | -56.02% |
| 1 Year Change | -62.32% |
| 3 Year Change | n/a |
| 5 Year Change | -37.75% |
| Change since IPO | -85.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6562 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 1.8% | 9.1% | 0.9% |
| 1Y | -62.3% | 15.5% | 28.9% |
Return vs Industry: 6562 underperformed the TW Biotechs industry which returned -18.2% over the past year.
Return vs Market: 6562 underperformed the TW Market which returned 31.7% over the past year.
Price Volatility
| 6562 volatility | |
|---|---|
| 6562 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6562's share price has been volatile over the past 3 months.
Volatility Over Time: 6562's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Chei-Hsiang Chen | www.ubi-pharma.com |
UBI Pharma Inc. develops, manufactures, and sells pharmaceutical products in Taiwan. The company offers protein drugs and formulations of molecule products; and develops biobetters and specialty injectables. Its product portfolio includes film coated, Virapine, and Efanzy tablets, as well as Terbutaline; and Levetir concentrate solution for infusion.
UBI Pharma Inc. Fundamentals Summary
| 6562 fundamental statistics | |
|---|---|
| Market cap | NT$1.68b |
| Earnings (TTM) | NT$803.00k |
| Revenue (TTM) | NT$648.63m |
2,097x
P/E Ratio2.6x
P/S RatioIs 6562 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6562 income statement (TTM) | |
|---|---|
| Revenue | NT$648.63m |
| Cost of Revenue | NT$451.50m |
| Gross Profit | NT$197.12m |
| Other Expenses | NT$196.32m |
| Earnings | NT$803.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0068 |
| Gross Margin | 30.39% |
| Net Profit Margin | 0.12% |
| Debt/Equity Ratio | 7.9% |
How did 6562 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/12 19:28 |
| End of Day Share Price | 2024/05/10 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
UBI Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|